BIOMAT Database Logo BIOMAT Database Logo

Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin VIa receptor antagonist, on human arterial coronary bypass graft. 1995

J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Department of Cardiac Surgery, University of Melbourne, Austin, Australia.

1. The effect of vasopressin receptor antagonists varies between analogues (peptide, non-peptide) and across species. In this study the effect of the novel non-peptide vasopressin V1a receptor antagonist SR 49059 on human internal mammary arteries was investigated. 2. SR 49059 produced a potent, concentration-dependent, inhibitory effect on vasopressin-induced contraction of human coronary bypass graft internal mammary arteries. Both SR 49059 (1 mumol/l) and a peptide selective V1a antagonist ([d(CH2)5sarcosine7]arginine vasopressin) (1 mumol/l) abolished vasopressin-induced contraction. The non-peptide V1a receptor antagonist OPC-21268 (1 mumol/l) had no effect on vasopressin-induced contraction. 3. The effect of SR 49059 was specific to vascular vasopressin receptors as noradrenaline-induced contraction was not influenced by SR 49059. 4. The results of this study in vitro indicate that the non-peptide SR 49059 is a potent, specific vasopressin V1a receptor antagonist in the human internal mammary artery and suggest that it may be a useful tool for studying the pathophysiological role of vasopressin in man.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008323 Mammary Arteries Arteries originating from the subclavian or axillary arteries and distributing to the anterior thoracic wall, mediastinal structures, diaphragm, pectoral muscles and mammary gland. Internal Mammary Artery,Internal Thoracic Artery,Arteries, Internal Mammary,Arteries, Internal Thoracic,Arteries, Mammary,Artery, Internal Mammary,Artery, Internal Thoracic,Artery, Mammary,Internal Mammary Arteries,Internal Thoracic Arteries,Mammary Arteries, Internal,Mammary Artery,Mammary Artery, Internal,Thoracic Arteries, Internal,Thoracic Artery, Internal
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D006727 Hormone Antagonists Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. Antagonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D001158 Arteries The vessels carrying blood away from the heart. Artery
D065092 Antidiuretic Hormone Receptor Antagonists Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS. Antidiuretic Hormone Antagonist,Antidiuretic Hormone Receptor Antagonist,Vasopressin Antagonist,Vasopressin Receptor Antagonist,Antidiuretic Hormone Antagonists,Vasopressin Antagonists,Vasopressin Receptor Antagonists,Antagonist, Antidiuretic Hormone,Antagonist, Vasopressin,Antagonist, Vasopressin Receptor,Antagonists, Antidiuretic Hormone,Antagonists, Vasopressin,Antagonists, Vasopressin Receptor,Hormone Antagonist, Antidiuretic,Hormone Antagonists, Antidiuretic,Receptor Antagonist, Vasopressin,Receptor Antagonists, Vasopressin

Related Publications

J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
April 1997, British journal of obstetrics and gynaecology,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.
February 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effect of the non-peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium.
July 1996, Acta obstetricia et gynecologica Scandinavica,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans.
November 1997, Hypertension (Dallas, Tex. : 1979),
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effects of SR 49059, a non-peptide antagonist of vasopressin V1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits.
January 1995, Fundamental & clinical pharmacology,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells.
September 2002, Journal of hypertension,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
February 1994, Biochemical pharmacology,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.
October 2000, Rheumatology (Oxford, England),
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
January 1995, The American journal of physiology,
J J Liu, and J R Chen, and B B Buxton, and C I Johnston, and L M Burrell
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
December 1996, The Journal of clinical investigation,
Copied contents to your clipboard!